|

A Study of Chinese Congenital Bicuspid Aortic Valve

RECRUITINGSponsored by Ruijin Hospital
Actively Recruiting
SponsorRuijin Hospital
Started2025-01-18
Est. completion2029-12-31
Eligibility
Age14 Years – 60 Years
Healthy vol.Accepted

Summary

Pervious studies indicated that the prevalence of bicuspid aortic valve(BAV) might be higher in China. There is a familial predisposition to the development of BAV. The study analyzed epidemiological data on selected BAV and established a BAV cohort to observe disease progression and treatment outcomes.

Eligibility

Age: 14 Years – 60 YearsHealthy volunteers accepted
Inclusion Criteria:

* The patients were aged 14-60 years;
* Definitive diagnosis of BAV by imaging (echocardiography, aortic CTA, cardiac magnetic resonance, etc.)
* Patients were informed about the nature of the study and agreed to participate in all the terms of the study and signed an informed consent form approved by the ethics committee.

Exclusion Criteria:

* Poor patient compliance and inability to complete follow-up visits as required;
* Rheumatic heart valve disease, other organic valve disease.
* Hyperthyroidism, severe anemia, and other factors that significantly affect hemodynamics.
* Other circumstances that the researcher believes should be excluded.

Conditions2

Bicuspid Aortic Valve (BAV)Heart Disease

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.